{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T04:51:19Z","timestamp":1654059079629},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12185-021-03223-6","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T10:29:38Z","timestamp":1632220178000},"page":"54-60","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ability of final PET\/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"115","author":[{"given":"Laura","family":"Galvez-Carvajal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Reinaldo","family":"Ch\u00edcharo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Espeso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"issue":"4","key":"3223_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220\u201341.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3223_CR2","first-page":"325","volume":"5","author":"SS Donaldson","year":"1999","unstructured":"Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin\u2019s disease\u2013finding the balance between cure and late effects. Cancer J Sci Am. 1999;5(6):325\u201333.","journal-title":"Cancer J Sci Am"},{"issue":"3","key":"3223_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","volume":"32","author":"GP Canellos","year":"2014","unstructured":"Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32(3):163\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3223_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1111961","volume":"366","author":"RM Meyer","year":"2012","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2012;366(5):399\u2013408.","journal-title":"N Engl J Med"},{"issue":"5","key":"3223_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.15838","volume":"185","author":"A Pavlovsky","year":"2019","unstructured":"Pavlovsky A, Fernandez I, Kurgansky N, Prates V, Zoppegno L, Negri P, et al. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Br J Haematol. 2019;185(5):865\u201373.","journal-title":"Br J Haematol"},{"key":"3223_CR6","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. JCO. 2019;37:2835.","journal-title":"JCO"},{"issue":"17","key":"3223_CR7","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(17):1598\u2013607.","journal-title":"N Engl J Med"},{"issue":"16","key":"3223_CR8","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017;35(16):1786\u201394.","journal-title":"J Clin Oncol"},{"issue":"9828","key":"3223_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791\u20139.","journal-title":"Lancet"},{"issue":"10","key":"3223_CR10","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1182\/blood-2008-06-155820","volume":"112","author":"C Kobe","year":"2008","unstructured":"Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112(10):3989\u201394.","journal-title":"Blood"},{"issue":"12","key":"3223_CR11","doi-asserted-by":"publisher","first-page":"e26681","DOI":"10.1002\/pbc.26681","volume":"64","author":"KS Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez KS, Schwartz CL, Chen L, Constine LS, Chauvenet A, de Alarc\u00f3n PA. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: a Children\u2019s Oncology Group report. Pediatr Blood Cancer. 2017;64(12):e26681.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"3223_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/cncr.30979","volume":"124","author":"TO Henderson","year":"2018","unstructured":"Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, et al. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children\u2019s Oncology Group (COG AHOD0031) comparative analysis: outcomes of AYAs With Hodgkin Lymphoma. Cancer. 2018;124(1):136\u201344.","journal-title":"Cancer"},{"issue":"1","key":"3223_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1023\/A:1008357126404","volume":"12","author":"M de Wit","year":"2001","unstructured":"de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin\u2019s lymphoma. Ann Oncol. 2001;12(1):29\u201337.","journal-title":"Ann Oncol"},{"issue":"2","key":"3223_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1046\/j.1365-2141.2001.03169.x","volume":"115","author":"K Spaepen","year":"2001","unstructured":"Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin\u2019s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115(2):272\u20138.","journal-title":"Br J Haematol"},{"issue":"10","key":"3223_CR15","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood.V98.10.2930","volume":"98","author":"MR Weihrauch","year":"2001","unstructured":"Weihrauch MR, Re D, Scheidhauer K, Ans\u00e9n S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98(10):2930\u20134.","journal-title":"Blood"},{"issue":"1","key":"3223_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1148\/radiol.2441060810","volume":"244","author":"NG Schaefer","year":"2007","unstructured":"Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET\/CT after first-line therapy\u2014Is biopsy of FDG-avid lesions still needed? Radiology. 2007;244(1):257\u201362.","journal-title":"Radiology"},{"issue":"8","key":"3223_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257\u201360.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"3223_CR18","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1007\/s00259-017-3714-4","volume":"44","author":"E Hindi\u00e9","year":"2017","unstructured":"Hindi\u00e9 E, Mesguich C, Bouabdallah K, Milpied N. Advanced Hodgkin\u2019s lymphoma: end-of-treatment FDG-PET should be maintained. Eur J Nucl Med Mol Imaging. 2017;44(8):1254\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3223_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","volume":"39","author":"PL Zinzani","year":"2012","unstructured":"Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin\u2019s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39(1):4\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"3223_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjh.14292","volume":"175","author":"C Mesguich","year":"2016","unstructured":"Mesguich C, Cazeau A-L, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, et al. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016;175(4):652\u201360.","journal-title":"Br J Haematol"},{"key":"3223_CR21","unstructured":"Domingo-Domenech E, Ramchandren R, Rueda A, Trn\u011bn\u00fd M, Feldman T, Lee HJ, et al. Nivolumab m\u00e1s doxorrubicina, vinblastina y dacarbazina para linfoma de Hodgkin cl\u00e1sico avanzado reci\u00e9n diagnosticado: seguimiento ampliado de dos a\u00f1os de la cohorte del estudio fase 2 CHECKMATE 205. Spanish Society Oncology Medical Congress 2019. P-Dest 51. 22\u201325 Oct."},{"issue":"Suppl 1","key":"3223_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/A:1008317426152","volume":"11","author":"M Sieber","year":"2000","unstructured":"Sieber M, Engert A, Diehl V. Treatment of Hodgkin\u2019s disease: results and current concepts of the German Hodgkin\u2019s Lymphoma Study Group. Ann Oncol. 2000;11(Suppl 1):81\u20135.","journal-title":"Ann Oncol"},{"issue":"21","key":"3223_CR23","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V, Armitage JO, Assouline D, Bj\u00f6rkholm M, Brusamolino E, et al. A prognostic score for advanced Hodgkin\u2019s disease. N Engl J Med. 1998;339(21):1506\u201314.","journal-title":"N Engl J Med"},{"issue":"5","key":"3223_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3223_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.13441","volume":"170","author":"HJA Adams","year":"2015","unstructured":"Adams HJA, Nievelstein RAJ, Kwee TC. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis. Br J Haematol. 2015;170(3):356\u201366.","journal-title":"Br J Haematol"},{"issue":"2","key":"3223_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","volume":"20","author":"R-O Casasnovas","year":"2019","unstructured":"Casasnovas R-O, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202\u201315.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3223_CR27","first-page":"349","volume":"57","author":"Z Molnar","year":"2010","unstructured":"Molnar Z, Simon Z, Borbenyi Z, Deak B, Galuska L, Keresztes K, et al. Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long term follow-up results. Neoplasma. 2010;57(4):349\u201354.","journal-title":"Neoplasma"},{"issue":"2","key":"3223_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1590\/S1807-59322007000200005","volume":"62","author":"LF Pracchia","year":"2007","unstructured":"Pracchia LF, Chaves AAR, Cerci JJ, Soares Junior J, Meneghetti JC, Buccheri V. Metabolic test with fluorine-18-fluorodeoxyglucose in staging and detection of residual tumor or recurrence in Hodgkin lymphoma. Clinics (Sao Paulo). 2007;62(2):121\u20136.","journal-title":"Clinics (Sao Paulo)"},{"issue":"4","key":"3223_CR29","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/annonc\/mdq549","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin\u2019s lymphoma. Ann Oncol. 2011;22(4):910\u20135.","journal-title":"Ann Oncol"},{"issue":"6","key":"3223_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.23994","volume":"90","author":"L Rigacci","year":"2015","unstructured":"Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, et al. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the fondazione italiana linfomi (FIL): Interim-FDG-PET and early stage Hodgkin\u2019s disease. Am J Hematol. 2015;90(6):499\u2013503.","journal-title":"Am J Hematol"},{"issue":"25","key":"3223_CR31","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374(25):2419\u201329.","journal-title":"N Engl J Med"},{"key":"3223_CR32","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1182\/blood.2019000719","volume":"134","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Li H, Sch\u00f6der H, Straus DJ, Moskowitz CH, Leblanc M, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach for stage III\/IV Hodgkin lymphoma. Blood. 2019;134:1238.","journal-title":"Blood"},{"issue":"5","key":"3223_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","volume":"36","author":"A Gallamini","year":"2018","unstructured":"Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mul\u00e9 A, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 Trial. JCO. 2018;36(5):454\u201362.","journal-title":"JCO"},{"issue":"22","key":"3223_CR34","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413\u201325.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03223-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03223-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03223-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T12:04:15Z","timestamp":1642334655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03223-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3223"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03223-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest, financial or otherwise. Lectures and advisory fees from Takeda and BMS. Investigational fee from Celgene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}